¼¼°èÀÇ ÆÁ¼Òº¸(Tibsovo) ½ÃÀå º¸°í¼­(2025³â)
Tibsovo Global Market Report 2025
»óǰÄÚµå : 1769775
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,272,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,065,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,859,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ÆÁ¼Òº¸ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ¿¹Ãø±â°£ Áß¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Á¤¹ÐÁ¾¾çÇÐÀÇ Çõ½Å, Àü·«Àû Á¦ÈÞ¿Í ÆÄÆ®³Ê½ÊÀÇ È®´ë, ÀúºÐÀÚ ÀǾàǰÀÇ Çõ½Å ÁøÀü, ±ÔÁ¦´ç±¹ÀÇ Çã°¡, Ä¡·á ÇÁ·ÎÅäÄÝÀÇ ÁøÈ­ µîÀÌ ÀÖ½À´Ï´Ù.

±Þ¼º °ñ¼ö¼º ¹éÇ÷º´ÀÇ À¯º´·ü Áõ°¡´Â ¾ÕÀ¸·Î ÆÁ¼Òº¸ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ À¯ÇüÀÇ ¹éÇ÷º´À» ¹ßº´Çϱ⠽¬¿î ¿¬·ÉÃþ¿¡ À̸£´Â »ç¶÷ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¹æ, Áúº´ÀÇ ÁøÇàÀ» ¾ïÁ¦Çϰí, Ä¡·á ¹ÝÀÀÀ» °³¼±Çϰí, »ýÁ¸ ¼ºÀûÀ» Çâ»ó½ÃÅ´À¸·Î½á, AML¿¡ ´ëóÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 2¿ù, Leukemia FoundationÀº 2022³âºÎÅÍ 2035³â±îÁö 7,000¸í ÀÌ»óÀÇ ¼Ò¾Æ, 6,000¸í ÀÌ»óÀÇ ÀþÀº ¼ºÀÎ, 10¸¸ 8,000¸í ÀÌ»óÀÇ ¼ºÀÎ(25-65¼¼)ÀÌ, ÁÖ·Î ALL, AML, ºñÈ£ÁöŲ ¸²ÇÁÁ¾À» Æ÷ÇÔÇÑ Ç÷¾×¾ÏÀ¸·Î Áø´ÜµÈ´Ù°í º¸°íÇß½À´Ï´Ù.

ÆÁ¼Òº¸ ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷Àº ¾àÁ¦ÀÇ ¸®Ä¡¸¦ ³ÐÈ÷°í IDH1 º¯À̾Ͽ¡¼­ÀÇ ¸®´õ½ÊÀ» À¯ÁöÇϱâ À§ÇØ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ Ãëµæ¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 10¿ù, ÇÁ¶û½º Á¦¾àȸ»ç Servier Laboratoires´Â À¯·´ À§¿øÈ¸·ÎºÎÅÍ ÆÁ¼Òº¸(À̺¸½Ãµ¥´Õ Á¤Á¦)ÀÇ ½ÂÀÎÀ» ÃëµæÇϰí, Ä¡·á°¡ °ï¶õÇÑ 2Á¾ÀÇ ¾ÏÁ¾¿¡ ´ëÇÑ À¯·´ ÃÖÃÊ·Î À¯ÀÏÇÑ IDH1 Ç¥Àû Ä¡·áÁ¦À¸·Î¼­ Çã°¡µÇ¾ú½À´Ï´Ù. R132 µ¹¿¬º¯À̸¦ °®´Â ½Å±Ô Áø´Ü AML ȯÀÚ¿¡ ´ëÇÑ ¾ÆÀÚ½ÃÆ¼µò°úÀÇ º´¿ë ¿ä¹ý, Àû¾îµµ 1ȸÀÇ Àü½Å ¿ä¹ý °æ·ÂÀÌ ÀÖ´Â µ¿º¯À̸¦ °®´Â ±¹¼Ò ÁøÇ༺ ¶Ç´Â ÀüÀ̼º ´ã°ü¾ÏÀ» °¡Áø ¼ºÀΠȯÀÚ¿¡ ´ëÇÑ ´ÜÀÏ ¿ä¹ýÀ¸·Î Çã°¡µÇ¾ú½À´Ï´Ù. Èñ±Í Áúº´ ÀǾàǰÀÇ ÁöÁ¤À» ¹ÞÀº À̹ø ½ÂÀÎÀº Áß¿äÇÑ ¹ÌÃæÁ· ÀÇ·á ¿ä±¸¸¦ ÃæÁ·ÇÏ´Â °ÍÀ¸·Î, ÀÌ·¯ÇÑ È¯ÀÚÀÇ °á°ú¿Í QOL °³¼±¿¡ »õ·Î¿î Èñ¸ÁÀ» °¡Á®´ÙÁÝ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦32Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦33Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦34Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦35Àå ºÎ·Ï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Tibsovo is an oral targeted therapy mainly prescribed for adults diagnosed with acute myeloid leukemia (AML) or cholangiocarcinoma that exhibit a specific mutation in the IDH1 gene. By targeting and inhibiting the mutated IDH1 enzyme, Tibsovo lowers the production of an abnormal metabolite that facilitates cancer cell proliferation, thereby aiding in the restoration of normal cell differentiation and decelerating disease advancement.

Tibsovo is available in various forms including tablets, capsules, combination therapies, and injectable options. The tablet form, which contains ivosidenib, is a convenient oral solid dosage designed for once-daily use. The drug can be administered both orally and intravenously and is distributed through hospital pharmacies, retail outlets, and online platforms. It serves several applications such as cancer therapy, AML treatment, chemotherapy, and precision-targeted therapies. These products are utilized by a range of end users including hospitals, specialized clinics, research centers, and homecare environments.

The tibsovo market research report is one of a series of new reports from The Business Research Company that provides tibsovo market statistics, including tibsovo industry global market size, regional shares, competitors with a tibsovo market share, detailed tibsovo market segments, market trends and opportunities, and any further data you may need to thrive in the tibsovo industry. This tibsovo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tibsovo market size has grown strongly in recent years. It will grow from $0.99 billion in 2024 to $1.08 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. Growth in the historical period has been driven by the rising incidence of AML, increased identification of IDH1 mutations among cancer patients, enhanced awareness around targeted treatments, and a surge in oncology-focused research and development.

The tibsovo market size is expected to see strong growth in the next few years. It will grow to $1.55 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. This anticipated expansion is due to the rising preference for targeted cancer medications, broader use of IDH1 inhibitors, heightened investment in biopharmaceutical R&D, and favorable regulatory pathways. Key trends anticipated during the forecast period include growth in precision oncology innovations, strategic alliances and partnerships, progress in small-molecule drug innovations, regulatory green lights, and evolution in therapeutic protocols.

The increasing prevalence of acute myeloid leukemia is expected to propel the growth of the Tibsovo market going forward. Acute myeloid leukemia (AML) is an aggressively progressing cancer of the blood and bone marrow that directly impacts blood cell production, immune function, and overall physical health. This rise in prevalence is largely attributed to the global increase in the aging population, as AML primarily affects older adults. With longer life expectancy, more individuals are reaching the age group most vulnerable to developing this type of leukemia. Tibsovo addresses AML by targeting IDH1-mutated cancer cells to inhibit abnormal cell growth, reduce disease progression, improve treatment response, and enhance survival outcomes by restoring normal blood cell production. For example, in February 2023, the Leukemia Foundation, an Australia-based non-profit organization, reported that between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults (aged 25-65) are expected to be diagnosed with blood cancers, primarily including ALL, AML, and non-Hodgkin lymphoma. As a result, the rising prevalence of acute myeloid leukemia is fueling the growth of the Tibsovo market.

Major companies operating in the Tibsovo market are focusing on obtaining regulatory approvals to broaden the drug's reach and sustain leadership in IDH1-mutated cancers. Regulatory approvals refer to the official permissions granted by health authorities that enable a drug to be legally marketed and used for designated medical conditions after its safety and effectiveness are confirmed. For instance, in October 2023, Servier Laboratoires, a France-based pharmaceutical company, received approval from the European Commission for Tibsovo (ivosidenib tablets), making it the first and only IDH1-targeted therapy authorized in Europe for two difficult-to-treat cancer types. The drug is approved for use in combination with azacitidine for newly diagnosed AML patients with an IDH1 R132 mutation who are ineligible for standard induction chemotherapy, and as a monotherapy for adults with locally advanced or metastatic cholangiocarcinoma harboring the same mutation after at least one prior systemic treatment. This approval, which benefits from orphan drug designation, fulfills critical unmet medical needs and offers new hope for improved outcomes and quality of life for these patients.

In December 2023, Servier Group, a France-based pharmaceutical company offering Tibsovo (ivosidenib tablets) as a targeted therapy for patients with IDH1-mutated cancers, acquired exclusive rights to develop, manufacture, and commercialize Tibsovo from CStone Pharmaceuticals for $44 million. This strategic acquisition aims to expand Servier Group's presence in the rapidly growing China and Singapore markets by securing exclusive rights to Tibsovo. It also strengthens the company's oncology portfolio with a targeted therapy for IDH1-mutated cancers and accelerates patient access to this innovative treatment in these key regions. CStone Pharmaceuticals is a China-based biopharmaceutical company that specializes in oncology treatments.

Major players in the tibsovo market are Servier Laboratoires, and Agios Pharmaceuticals.

North America was the largest region in the tibsovo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tibsovo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tibsovo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tibsovo market consists of sales of products including oral tablets, extended-release tablets, soft gel capsules, intravenous injection, and subcutaneous injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tibsovo Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tibsovo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for tibsovo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tibsovo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

1) By Tablets; Oral Tablets; Extended-Release Tablets

2) By Capsules; Soft Gel Capsules; Hard Gel Capsules

3) By Combination Therapy; Tibsovo + Chemotherapy Agents; Tibsovo + Targeted Therapy Agents

4) By Injectable Forms; Intravenous Injection; Subcutaneous Injection

Table of Contents

1. Executive Summary

2. Tibsovo Market Characteristics

3. Tibsovo Market Trends And Strategies

4. Tibsovo Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Tibsovo Growth Analysis And Strategic Analysis Framework

6. Tibsovo Market Segmentation

7. Tibsovo Market Regional And Country Analysis

8. Asia-Pacific Tibsovo Market

9. China Tibsovo Market

10. India Tibsovo Market

11. Japan Tibsovo Market

12. Australia Tibsovo Market

13. Indonesia Tibsovo Market

14. South Korea Tibsovo Market

15. Western Europe Tibsovo Market

16. UK Tibsovo Market

17. Germany Tibsovo Market

18. France Tibsovo Market

19. Italy Tibsovo Market

20. Spain Tibsovo Market

21. Eastern Europe Tibsovo Market

22. Russia Tibsovo Market

23. North America Tibsovo Market

24. USA Tibsovo Market

25. Canada Tibsovo Market

26. South America Tibsovo Market

27. Brazil Tibsovo Market

28. Middle East Tibsovo Market

29. Africa Tibsovo Market

30. Tibsovo Market Competitive Landscape And Company Profiles

31. Global Tibsovo Market Competitive Benchmarking And Dashboard

32. Key Mergers And Acquisitions In The Tibsovo Market

33. Recent Developments In The Tibsovo Market

34. Tibsovo Market High Potential Countries, Segments and Strategies

35. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â